Guided Therapeutics Selects I.T.E.M. Medical Technologies Group to Distribute LuViva® Advanced Cervical Scan in Turkey and Select Territories

Guided Therapeutics Selects I.T.E.M. Medical Technologies Group to Distribute LuViva® Advanced Cervical Scan in Turkey and Select Territories

Investors:Cameron AssociatesAlison Ziegler, 212-554-5469orGuided TherapeuticsBill Wells, 770-242-8723 Ext. 241

(OTCBB: GTHP) (OTCQB: GTHP) today announced that it has signed a definitive agreement granting exclusive distribution rights for LuViva Advanced Cervical Scan in Turkey, Iraq and Azerbaijan. The agreement brings to 12 the number of territories under definitive distribution relationships in Europe, North America, Asia and Africa.

The agreement is for three years. An initial shipment of one LuViva demonstration unit was made in September, 2012 and product launch is expected upon compliance with the CE Mark, Third Edition, which is anticipated prior to year end.

“The selection of I.T.E.M. as a qualified distributor for LuViva establishes a bridge from Europe to Asia and aligns us with a highly-experienced team that has demonstrated success in introducing and selling new technologies into a rapidly developing market eager for medical innovation,” said Mark L. Faupel, Ph.D., CEO and President of Guided Therapeutics, Inc. “Due diligence is also ongoing in a number of other territories with additional agreements pending.”

Zafer Yazici, CEO and President of I.T.E.M. Medical Technologies Group, added, “Since our beginning, we have been committed to bringing advanced medical technologies to this region of the world. LuViva's innovative technology will not only complement our current gynecology product offerings, but allows us to raise the bar in women's healthcare in our region."

Each year in Turkey, about 2 million women undergo Pap test screening for cervical cancer, with as many as 200,000 receiving an abnormal Pap result. These women are then scheduled for a follow-up exam, called a colposcopy, which typically includes a painful biopsy of cervical tissue. LuViva is designed to be used before colposcopy to identify women without disease and preventing them from receiving these unnecessary biopsies. Besides the obvious reduction in patient discomfort, there will also be a significant reduction in healthcare costs. All of this is accomplished utilizing a painless test that takes less than one minute and produces a result immediately at the point of care.

LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which eliminates costly, painful and unnecessary testing. LuViva is designed for use with women who have undergone initial screening and are called back for follow up with a colposcopy examination, which in many cases involves taking a biopsy of the cervix. The device is used in conjunction with the LuViva Cervical Guide single-use patient interface and calibration disposable.

I.T.E.M Innovations Group is a leading medical technology consortium in Turkey. The companies within the I.T.E.M. Group include ROTA ILERI CO. LTD. and NOVATEK CO. LTD., which were established in 1990 and have successfully introduced an impressive number of innovative medical technologies to the market. I.T.E.M Innovations Group has been one of the most dynamic, fast growing and trustworthy medical companies in the region for more than 20 years.

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) is developing a rapid and painless testing platform for the early detection of disease based on its patented biophotonic technology that utilizes light to detect disease at the cellular level. The Company’s first planned product is the LuVivaAdvanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial, with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. Guided Therapeutics has also entered into a partnership with Konica Minolta to develop a non-invasive test for the early detection of esophageal cancer using the technology platform. For more information, visit: .

Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics’ actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the uncertainty of capital to develop products, the uncertainty of regulatory approval of products, dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading “Risk Factors” in Guided Therapeutics’ reports filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2011, and subsequent quarterly reports.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.